RxDoctor Payments Data

Ximena Galarza-Rios, MD

Family Medicine · Albuquerque, NMNPI 1407879604

Payments from drug & device makers

$1,902in general payments, 2019–2025

Across 82 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$304
  • Lilly USA, LLC$293
  • Novo Nordisk$292
  • Exact Sciences$201
  • Pfizer$175
  • GSK$169
  • plus $469 from 10 others

What the payments were for

  • Food & beverage$1,902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,902 in reported general payments places this provider in the 85th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$91,128
Medicare patients
140
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide69$74,868
JardianceEmpagliflozin96$74,783
JanuviaSitagliptin Phosphate62$72,219
EliquisApixaban47$55,710
OzempicSemaglutide43$40,219
JanumetSitagliptin Phos/Metformin Hcl22$35,130
XareltoRivaroxaban19$21,104
MyrbetriqMirabegron11$15,559
Bydureon BciseExenatide Microspheres12$9,439
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$8,605
Fluticasone Propionate HfaFluticasone Propionate16$7,120
Combivent RespimatIpratropium/Albuterol Sulfate13$6,479
Levothyroxine Sodium418$5,732
Atorvastatin Calcium382$5,096
LantusInsulin Glargine,hum.Rec.Anlog28$4,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$35$107,34984 claims
Boehringer IngelheimJardiance, Combivent Respimat$128$81,262109 claims
Lilly USA, LLCTrulicity, Humalog$293$78,35682 claims
PfizerEliquis, Paxlovid$175$57,13976 claims
Novo NordiskOzempic$292$40,21943 claims
Astellas Pharma US IncMyrbetriq$43$15,55911 claims
AbbVieSynthroid$24$2,07631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →